10303. Denosumab

Nomenclature

CAS number: 615258-40-7
Anti-(human osteoclast differentiation factor) immunoglobulin G2 (human monoclonal AMG162 heavy chain) disulfide with human monoclonal AMG162 light chain, dimer; Anti-(human receptor activator of NF-κB ligand) immunoglobulin G2 (human monoclonal AMG162 heavy chain) disulfide with human monoclonal AMG162 light chain, dimer; AMG-162.

Description and references

Human monoclonal antibody directed against receptor activator of NF-κB ligand (RANKL) also known as osteoprotegerin ligand (OPGL). Inhibits the effects of RANKL on osteoclast differentiation and subsequent bone loss. Prepn: W. J. Boyle et al., WO 03002713 (2003 to Abgenix; Amgen); eidem, US 7364736 (2008 to Amgen). Clinical effect on bone mineral density in postmenopausal women: M. R. McClung et al., N. Engl. J. Med. 354, 821 (2006) DOI PubMed. Clinical evaluation in breast cancer-related bone metastases: A. Lipton et al., J. Clin. Oncol. 25, 4431 (2007) DOI PubMed; in rheumatoid arthritis: S. B. Cohen et al., Arthritis Rheum. 58, 1299 (2008) DOI PubMed. Review of clinical experience: E. M. Lewiecki, Expert Opin. Biol. Ther. 6, 1041-1050 (2006) DOI PubMed.

Therapeutic Category

Bone resorption inhibitor; antiosteoporotic.

Keywords

Bone Resorption Inhibitor; Antiosteoporotic